Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
CDXS's Cash to Debt is ranked higher than
84% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. CDXS: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CDXS' s Cash to Debt Range Over the Past 10 Years
Min: 2.71  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.53
CDXS's Equity to Asset is ranked lower than
66% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CDXS: 0.53 )
Ranked among companies with meaningful Equity to Asset only.
CDXS' s Equity to Asset Range Over the Past 10 Years
Min: -1.82  Med: 0.71 Max: 0.79
Current: 0.53
-1.82
0.79
Interest Coverage No Debt
CDXS's Interest Coverage is ranked higher than
69% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CDXS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CDXS' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 5
Z-Score: -3.09
M-Score: -0.68
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -11.45
CDXS's Operating margin (%) is ranked higher than
64% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. CDXS: -11.45 )
Ranked among companies with meaningful Operating margin (%) only.
CDXS' s Operating margin (%) Range Over the Past 10 Years
Min: -155.16  Med: -54.13 Max: -6.65
Current: -11.45
-155.16
-6.65
Net-margin (%) -11.67
CDXS's Net-margin (%) is ranked higher than
65% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. CDXS: -11.67 )
Ranked among companies with meaningful Net-margin (%) only.
CDXS' s Net-margin (%) Range Over the Past 10 Years
Min: -153.96  Med: -54.01 Max: -7.97
Current: -11.67
-153.96
-7.97
ROE (%) -22.82
CDXS's ROE (%) is ranked higher than
56% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. CDXS: -22.82 )
Ranked among companies with meaningful ROE (%) only.
CDXS' s ROE (%) Range Over the Past 10 Years
Min: -68.88  Med: -45.17 Max: -15.76
Current: -22.82
-68.88
-15.76
ROA (%) -12.11
CDXS's ROA (%) is ranked higher than
64% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. CDXS: -12.11 )
Ranked among companies with meaningful ROA (%) only.
CDXS' s ROA (%) Range Over the Past 10 Years
Min: -52.02  Med: -30.91 Max: -7.11
Current: -12.11
-52.02
-7.11
ROC (Joel Greenblatt) (%) -124.69
CDXS's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. CDXS: -124.69 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CDXS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -664.06  Med: -228.54 Max: -35.45
Current: -124.69
-664.06
-35.45
Revenue Growth (3Y)(%) -35.80
CDXS's Revenue Growth (3Y)(%) is ranked lower than
79% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. CDXS: -35.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CDXS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -28.85 Max: -35.8
Current: -35.8
EBITDA Growth (3Y)(%) 33.10
CDXS's EBITDA Growth (3Y)(%) is ranked higher than
86% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. CDXS: 33.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CDXS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 33.1
Current: 33.1
0
33.1
EPS Growth (3Y)(%) 2.50
CDXS's EPS Growth (3Y)(%) is ranked higher than
60% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. CDXS: 2.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CDXS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -26.15 Max: 46
Current: 2.5
0
46
» CDXS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

CDXS Guru Trades in Q1 2015

Jim Simons 461,900 sh (+45.76%)
» More
Q2 2015

CDXS Guru Trades in Q2 2015

Jim Simons 654,200 sh (+41.63%)
» More
Q3 2015

CDXS Guru Trades in Q3 2015

Jim Simons 727,300 sh (+11.17%)
» More
Q4 2015

CDXS Guru Trades in Q4 2015

Jim Simons 753,100 sh (+3.55%)
» More
» Details

Insider Trades

Latest Guru Trades with CDXS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 196.08
CDXS's Forward P/E is ranked lower than
96% of the 342 Companies
in the Global Biotechnology industry.

( Industry Median: 16.21 vs. CDXS: 196.08 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 6.80
CDXS's P/B is ranked lower than
91% of the 1128 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. CDXS: 6.80 )
Ranked among companies with meaningful P/B only.
CDXS' s P/B Range Over the Past 10 Years
Min: 0.83  Med: 2.09 Max: 10.33
Current: 6.8
0.83
10.33
P/S 3.49
CDXS's P/S is ranked higher than
78% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 9.03 vs. CDXS: 3.49 )
Ranked among companies with meaningful P/S only.
CDXS' s P/S Range Over the Past 10 Years
Min: 0.27  Med: 1.76 Max: 5.58
Current: 3.49
0.27
5.58
EV-to-EBITDA 290.89
CDXS's EV-to-EBITDA is ranked lower than
97% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 15.20 vs. CDXS: 290.89 )
Ranked among companies with meaningful EV-to-EBITDA only.
CDXS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -644.8  Med: -5.20 Max: 439.2
Current: 290.89
-644.8
439.2
Current Ratio 2.52
CDXS's Current Ratio is ranked lower than
68% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. CDXS: 2.52 )
Ranked among companies with meaningful Current Ratio only.
CDXS' s Current Ratio Range Over the Past 10 Years
Min: 1.14  Med: 2.62 Max: 3.98
Current: 2.52
1.14
3.98
Quick Ratio 2.47
CDXS's Quick Ratio is ranked lower than
65% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. CDXS: 2.47 )
Ranked among companies with meaningful Quick Ratio only.
CDXS' s Quick Ratio Range Over the Past 10 Years
Min: 1.07  Med: 2.46 Max: 3.75
Current: 2.47
1.07
3.75
Days Inventory 57.74
CDXS's Days Inventory is ranked higher than
78% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. CDXS: 57.74 )
Ranked among companies with meaningful Days Inventory only.
CDXS' s Days Inventory Range Over the Past 10 Years
Min: 31.91  Med: 45.73 Max: 64.46
Current: 57.74
31.91
64.46
Days Sales Outstanding 111.85
CDXS's Days Sales Outstanding is ranked lower than
76% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. CDXS: 111.85 )
Ranked among companies with meaningful Days Sales Outstanding only.
CDXS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 31.19  Med: 52.25 Max: 92.67
Current: 111.85
31.19
92.67
Days Payable 56.72
CDXS's Days Payable is ranked lower than
52% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. CDXS: 56.72 )
Ranked among companies with meaningful Days Payable only.
CDXS' s Days Payable Range Over the Past 10 Years
Min: 43.52  Med: 175.37 Max: 503.44
Current: 56.72
43.52
503.44

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 13.93
CDXS's Price/Net Current Asset Value is ranked lower than
77% of the 883 Companies
in the Global Biotechnology industry.

( Industry Median: 5.05 vs. CDXS: 13.93 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CDXS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.19  Med: 4.28 Max: 48.63
Current: 13.93
2.19
48.63
Price/Tangible Book 9.51
CDXS's Price/Tangible Book is ranked lower than
76% of the 1034 Companies
in the Global Biotechnology industry.

( Industry Median: 9.50 vs. CDXS: 9.51 )
Ranked among companies with meaningful Price/Tangible Book only.
CDXS' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.34  Med: 3.05 Max: 16.91
Current: 9.51
1.34
16.91
Price/Median PS Value 1.98
CDXS's Price/Median PS Value is ranked lower than
86% of the 846 Companies
in the Global Biotechnology industry.

( Industry Median: 0.87 vs. CDXS: 1.98 )
Ranked among companies with meaningful Price/Median PS Value only.
CDXS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.18  Med: 0.94 Max: 2.85
Current: 1.98
0.18
2.85
Earnings Yield (Greenblatt) (%) -3.56
CDXS's Earnings Yield (Greenblatt) (%) is ranked higher than
59% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. CDXS: -3.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CDXS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -26.2  Med: 0.00 Max: 0
Current: -3.56
-26.2
0

More Statistics

Revenue(Mil) $44
EPS $ -0.14
Beta-1.34
Short Percentage of Float1.01%
52-Week Range $3.02 - 5.65
Shares Outstanding(Mil)40.31

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 42 47 55 67
EPS($) -0.18 -0.07 0.02 0.13
EPS without NRI($) -0.18 -0.07 0.02 0.13

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:4QK.Germany,
Codexis Inc was incorporated in Delaware in January 2002. The Company is a developer of proprietary biocatalysts, which are enzymes or microbes that initiate or accelerate chemical reactions. Its proven technologies enable scale-up and implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable process development, from research to manufacturing. The Company has commercialized its technology and products in the pharmaceuticals market. The pharmaceutical customers, which include several pharmaceutical companies, use its technology, products and services in their manufacturing process development, including in the production of some of the world's bestselling and fastest growing drugs. It has recently started to use its technology to develop biocatalysts for use in the fine chemicals markets. The fine chemicals market is similar to its pharmaceutical business and consists of several large market segments, including food, animal feed, polymers, flavors and fragrances and agricultural chemicals, and so it is a natural fit for its technology. Its technology is also currently being used by a customer to manufacture butadiene, an intermediate for the manufacture of polymers. The Company's pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (API), and Codex Biocatalyst Kits and Panels. It markets and sells enzymes, development services and Codex Biocatalyst Kits and Panels screening tools that enable novel manufacturing processes for APIs and their precursor pharmaceutical intermediates. It also markets and sells pharmaceutical intermediates that are manufactured using its custom enzymes. The registered and pending United States and foreign trademarks include Codexis, Codex, CodeEvolver, CodeXporter, CodeXol, CodeXyme, Powered by CodeEvolver, We Are Biocatalysis, Mosaic, Sage, Microcyp, Hit from a Kit, Prosar and a Codexis and design mark. The competitors include Solvias Inc. and Takasago International Corporation who use metal-based chemical reactions for their pharmaceutical products, industrial enzyme companies, such as Novozymes, as well as subsidiaries of larger pharmaceutical companies, such as DSM, Cambrex Corporation and Almac Group Ltd. There is also competition in the customized and optimized enzyme area from several small European companies, such as BRAIN AG, C-LEcta GmbH and evocatal GmbH. The Company's operations comply with environmental laws and regulations.
» More Articles for NAS:CDXS

Headlines

Articles On GuruFocus.com
Weekly 3-Year Lows Highlight: SEAS, AMTG, AHH, NCTY, CDXS Dec 30 2013 
Weekly CEO Buys Highlight: AKAM, DRC, MDRX, MTG, CDXS Mar 17 2013 
A New Beginning for Codexis? Mar 08 2013 
Weekly CFO Buys Highlight: ASNB, FXCM, CDXS, VTNC, BRS Sep 24 2012 

More From Other Websites
4 Industrial Stocks Set to Surprise this Earnings Season Feb 09 2016
Pentair (PNR) Beats on Q4 Earnings, Retains 2016 Guidance Feb 02 2016
CDXS and LOGI are Aggressive Growth Stocks Jan 28 2016
Codexis (CDXS) Catches Eye: Stock Adds 7.9% in Session Jan 25 2016
Codexis, Morgan Stanley, Goldcorp, Turquoise Hill Resources and Franco-Nevada highlighted as Zacks... Jan 22 2016
Codexis (CDXS) Strong Industry, Solid Earnings Estimate Revisions Jan 19 2016
Zacks Investment Ideas feature highlights: General Employment, ARRIS International, Centene, Zayo... Jan 13 2016
Best Investments for 2016 Jan 12 2016
Why This Codexis Analyst Is Confident Stock Is Worth $6 Jan 06 2016
Coverage initiated on Codexis by H.C. Wainwright Jan 06 2016
Codexis, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 24 2015
Can Codexis (CDXS) Stock Continue to Grow Earnings? Dec 23 2015
CODEXIS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD... Dec 22 2015
Codexis Signs Multi-year Extension of Contract with Merck to Supply Enzyme Used in Manufacture of... Dec 18 2015
Codexis Signs Multi-year Extension of Contract with Merck to Supply Enzyme Used in Manufacture of... Dec 18 2015
3 Reasons Momentum Stock Investors Will Love Codexis (CDXS) Dec 15 2015
Codexis (CDXS) Looks Good: Stock Adds 6.1% in Session Dec 11 2015
CODEXIS INC Financials Dec 08 2015
New Information Reveals Opportunity in Volatility - Research on Strongbridge Biopharma, Pacific... Nov 30 2015
Breeze-Eastern Corp (BZC): Are Hedge Funds Right About This Stock? Nov 26 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK